In this review:
This review discusses the evidence supporting the use of tacrolimus 0.1% ointment (Zematop®) for the management of atopic dermatitis in adults and adolescents. Topical tacrolimus is a non-steroidal, calcineurin inhibitor with low systemic absorption that does not cause skin atrophy. Tacrolimus 0.1% ointment has anti-inflammatory properties comparable to moderate-to-potent topical corticosteroids. Topical tacrolimus is a second-line treatment for patients aged 16 years and over with moderate-tosevere AD for the treatment of flares, and for maintenance treatment in patients with a high frequency of flares, i.e. ≥ 4 a year. Special Authority funding is available from October 2021 for those with facial AD who are unable to use topical corticosteroids. This review is sponsored by an educational grant from Douglas Pharmaceuticals.
Please login below to download this issue (PDF)